Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Gemcitabine and Erlotinib in Metastatic Pancreatic Cancer
NCT00550836Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2009
- Primary completion
- Nov 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Started Mar 2009; status: completed.
02
Drugs
panitumumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00550836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550836.